44 patents
Page 2 of 3
Utility
Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
16 Mar 21
The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 31 Oct 16
Utility
Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
9 Mar 21
Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RARα) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
Gabriel Ghiaur, Richard J. Jones, Alonso Salvador, Roshantha A. Chandraratna
Filed: 23 Nov 16
Utility
Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids
16 Feb 21
Provided herein are compounds useful for the preparation of compounds that have retinoid-like biological activity.
Roshantha A. Chandraratna, Vidyasagar Pradeep Vuligonda, Thomas Jacks, Peter Wade, Andrew Thompson
Filed: 24 Feb 20
Utility
Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
4 Jan 21
Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 11 Dec 19
Utility
Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
28 Dec 20
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 7 Nov 19
Utility
Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
28 Dec 20
Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 21 Nov 19
Utility
RAR selective agonists in combination with immune modulators for cancer immunotherapy
28 Dec 20
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 11 Dec 19
Utility
Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
7 Dec 20
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 14 Mar 19
Utility
Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
23 Nov 20
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 25 Mar 19
Utility
Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
16 Nov 20
The present specification provides methods of treating a muscular disorder with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 30 Oct 16
Utility
Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
19 Oct 20
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 18 Mar 19
Utility
Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
6 Jul 20
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 15 Apr 19
Utility
Autoimmune disorder treatment using RXR agonists
29 Jun 20
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Filed: 23 May 18
Utility
Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
29 Jun 20
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 8 Apr 19
Utility
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
18 May 20
The present specification provides RXR agonists with both remyelination promotion and immunomodulatory activities, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat a demyelination-related disorder by both promoting remyelination of neurons and modulating the immune system.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle, Martin E. Sanders
Filed: 5 Oct 14
Utility
Treatment of cancer with specific RXR agonists
23 Mar 20
A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
Roshantha A. Chandraratna
Filed: 16 Dec 18
Utility
Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
16 Mar 20
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 6 Mar 19
Utility
Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids
16 Mar 20
Provided herein are compounds useful for the preparation of compounds that have retinoid-like biological activity.
Roshantha A. Chandraratna, Vidyasagar Pradeep Vuligonda, Thomas Jacks, Peter Wade, Andrew Thompson
Filed: 15 Nov 18
Utility
RAR selective agonists in combination with immune modulators for cancer immunotherapy
13 Jan 20
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 25 Jun 19
Utility
RAR selective agonists in combination with immune modulators for cancer immunotherapy
13 Jan 20
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 22 Jul 19